This paper aims to outline the ethical concerns regarding the use of antidepressant medication in children and adolescents. Recent debates surrounding this issue have focused on the link between selective serotonin reuptake inhibitor use and an increased risk of suicidal thinking/behaviour, and weighed that against the benefit of the alleviation of depressive symptoms. It is argued here that such an approach is simplistic. There are several serious risks surrounding antidepressant use in the young that ought to be included in the equation, along with a consideration of the neuroethical concerns surrounding pharmacotherapy for affective disorders. Using the precautionary principle as a framework for analysis it is concluded that the risks are sufficiently serious and plausible that the prescribing of antidepressant medication to the young ought to be severely restricted; further it is imperative that the child and their parents are made fully aware of the risks, short-term and long-term, involved.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: None.
↵i The argument for the use of antidepressants in the paediatric population is that they have been effective in the treatment for adult-onset depression. However the two disorders may in fact have different underlying aetiologies.
↵ii Informed consent normally involves briefing the relevant parties as to the different treatment options available (including the option not to treat) mentioning the benefits, likelihood of success and possible risks.
↵iii Throughout this paper children and adolescents have been grouped together as most studies have used age ranges that fall into both categories. This is potentially misleading as depression in older adolescents may more closely resemble adult onset depression.
↵iv We have focused on fluoxetine as it is the only SSRI currently licensed for use in depression for children over 8-years-old. However other SSRIs and antidepressants are used off-label for depression and other conditions. The concerns about neurodevelopment remain the same and need to be addressed re: informed consent.
Read the full text or download the PDF:
Other content recommended for you
- Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting
- Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports
- Survey on self-reported psychotropic drug prescribing practices of eating disorder psychiatrists for the treatment of young people with anorexia nervosa
- Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data
- Long-term benzodiazepine use in patients taking antidepressants in a public health setting in Brazil: a cross-sectional study
- Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study
- A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database
- Depression, depressive symptoms and treatments in women who have recently given birth: UK cohort study
- Adverse drug reactions in childhood: a review of prospective studies and safety alerts
- Prestroke selective serotonin reuptake inhibitor use and functional outcomes after ischaemic stroke